ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Parker Institute and Xyphos to develop universal CAR T-cell therapies

by Ryan Cross
October 19, 2018 | APPEARED IN VOLUME 96, ISSUE 42

 

The Parker Institute for Cancer Immunotherapy and start-up Xyphos Biosciences are teaming up to develop universal and controllable CAR T-cell therapies that can treat many kinds of cancers. Whereas the two CAR T-cell therapies on the market are engineered to attack one particular protein, Xyphos is designing what it calls convertible CAR T cells, which can be redirected to many targets. The cells are activated by bispecific antibodies that bind a CAR T cell at one end and the cancer cell at the other end. Xyphos expects to test its first therapy in humans in early 2020.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment